Peer-influenced content. Sources you trust. No registration required. This is HCN.

Hospital Healthcare EuropeNovel Prostate Cancer Screening Test Highly Accurate

A group of UK researchers has created a novel prostate cancer (PaC) screening test (EpiSwitch) that, when combined with the prostate specific antigen (PSA) test, has a high degree of accuracy for detecting the cancer. The test is based on measurement of five chromosome conformations that were first discovered in association with advanced PaC.

The EpiSwitch test has a high positive predictive value for the diagnosis of PaC (92%) and a high negative predictive value (94%) when used in conjunction with the PSA level as a continuous variable, according to the researchers. The study’s authors advocated for additional research to investigate the test’s efficacy in larger patient samples, even though it was based on a scant number of patient samples.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form